Published in Breast Cancer Res Treat on January 01, 2005
Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol (2011) 2.16
A microRNA signature associated with early recurrence in breast cancer. PLoS One (2014) 1.00
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res (2013) 1.00
Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res (2011) 0.99
Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res (2008) 0.97
Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer (2009) 0.96
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat (2010) 0.86
Putative growth characteristics of micrometastatic breast cancer. Breast Cancer Res (2008) 0.85
Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Nat Rev Clin Oncol (2016) 0.84
Perspectives in anaesthesia for cancer surgery. J Cancer Res Clin Oncol (2013) 0.82
New concepts in breast cancer emerge from analyzing clinical data using numerical algorithms. Int J Environ Res Public Health (2009) 0.81
Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res (2014) 0.79
The reality in the surveillance of breast cancer survivors-results of a patient survey. Breast Cancer (Auckl) (2008) 0.78
Metastatic tumor dormancy in cutaneous melanoma: does surgery induce escape? Cancers (Basel) (2011) 0.77
Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. J Natl Cancer Inst (2015) 0.75
Multimodal hazard rate for relapse in breast cancer: quality of data and calibration of computer simulation. Cancers (Basel) (2014) 0.75
The effect of local therapy on breast cancer mortality: is there an age-interaction? Indian J Surg Oncol (2013) 0.75
Long-term Consequences of the Acute Neural-Inflammatory Stress Response in the Cancer Surgical Patient: New Findings and Perspectives. Int Anesthesiol Clin (2016) 0.75
Comment to Jatoi et al. report. Breast Cancer Res Treat (2005) 0.75
Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Res Treat (2017) 0.75
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth (2009) 8.28
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst (2004) 6.55
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol (2005) 6.31
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 5.40
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol (2004) 5.08
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat (2006) 4.42
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst (2005) 4.25
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res (2004) 3.90
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol (2005) 3.62
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol (2003) 3.58
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res (2008) 3.45
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res (2008) 3.32
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell (2011) 3.27
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development (2007) 3.07
Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology (2009) 3.07
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol (2010) 2.93
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82
REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol (2005) 2.82
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
Research with stored biological samples: what do research participants want? Arch Intern Med (2005) 2.43
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol (2004) 2.39
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol (2006) 2.24
Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg (2008) 2.14
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst (2007) 2.11
Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun (2003) 2.05
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res (2003) 2.01
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 2.01
Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells (2008) 1.96
REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer (2005) 1.93
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 1.93
Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res (2002) 1.91
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer (2003) 1.87
Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. J Natl Cancer Inst (2011) 1.84
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol (2013) 1.81
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res (2013) 1.80
The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res (2007) 1.79
Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res (2010) 1.77
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res (2008) 1.75
Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res (2006) 1.74
REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol (2005) 1.72
Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the Fsr system of Enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol (2006) 1.71
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol (2007) 1.70
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res (2006) 1.67
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res (2004) 1.67
Medical complications and outcomes after hip fracture repair. Arch Intern Med (2002) 1.65
Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology (2005) 1.59
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol (2005) 1.58
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 1.57
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res (2011) 1.56
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res (2011) 1.54
atxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J Bacteriol (2004) 1.52
To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med (2011) 1.52
The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res (2002) 1.51
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res (2009) 1.48
GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. Cancer Res (2009) 1.44
The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol (2007) 1.43
Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med (2010) 1.43
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res (2004) 1.42
Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer (2002) 1.41
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res (2010) 1.39
Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol (2004) 1.37
Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev (2002) 1.35
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res (2006) 1.35
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene (2002) 1.34
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat (2008) 1.34
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat (2006) 1.32
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat (2007) 1.31
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst (2009) 1.31
Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat (2008) 1.27
Reproducibility, sources of variability, pooling, and sample size: important considerations for the design of high-density oligonucleotide array experiments. J Gerontol A Biol Sci Med Sci (2004) 1.27
Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol (2007) 1.25
Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol (2003) 1.25
Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res (2005) 1.23
Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res (2006) 1.23